多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗支气管扩张的临床效果

Clinical effect of combination of Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule in the treatment of bronchiectasis

目的探讨多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗支气管扩张的临床效果。方法分析我院2016年2月～2018年5月收治的60例支气管扩张患者的临床资料,依据随机纸片法分为对照组(30例)和观察组(30例)。对照组患者采用小剂量罗红霉素治疗,观察组采用多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗。比较两组支气管扩张患者治疗前后的肺功能、呼吸困难评分和影像学评分情况,观察两组支气管扩张患者的临床疗效情况。结果两组支气管扩张患者治疗前1 s用力呼气容积(FEV_1)、用力肺活量(FVC)、呼气流量峰值(PEF)呼吸困难评分和影像学评分比较,差异均无统计学意义(P>0.05)。两组患者治疗后的FEV_1、FVC、PEF均高于治疗前,呼吸困难评分和影像学评分均低于治疗前,差异有统计学意义(P<0.05)。观察组患者治疗后的FEV_1、FVC、PEF均高于对照组,呼吸困难评分和影像学评分均低于对照组,差异有统计学意义(P<0.05)。观察组支气管扩张患者的临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗支气管扩张患者效果显著,肺功能明显提高,呼吸困难评分和影像学评分明显降低,值得临床推广应用。

Objective To investigate the clinical effect of Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule in the combination treatment of bronchiectasis. Methods The clinical data of 60 patients with bronchiectasis admitted to our hospital from February 2016 to May 2018 were analyzed. They were divided into the control group and the observation group by the random paper strip, 30 cases in each group. The patients in the control group were treated with low dose Roxithromycin, while the patients in the observation group were treated with Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule. The lung function, dyspnea score and imaging score of the patients with bronchiectasis before and after treatment were compared. The clinical efficacy in the two groups was observed. Results There were no significant differences in the first second forced expiratory volume (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), dyspnea score or imaging score between the two groups before treatment (P>0.05). After treatment, the values of FEV1,FVC and PEF in the two groups were higher than those before treatment, and the dyspnea and imaging scores were lower than those before treatment, with statistical significance (P<0.05). Compared with the control group, the FEV1, FVC and PEF of the observation group were higher, and the dyspnea and imaging scores were lower ,with statistical significance (P<0.05). The total effectiveness rate of clinical treatment of bronchiectasis patients in the observation group was higher than that in the control group, with statistical significance (P<0.05). Conclusion The combination of Doxofylline, Roxithromycin, and Eucalyptol Enteric Soft Capsule in the treatment of patients with bronchiectasis can remarkably improves the lung function, reduces the dyspnea and imaging scores, and is worthy of clinical application and promotion.